Implantation treatment method of slow release anticancer doxorubicin containing hydroxyapatite (DOX-HAP) complex. A basic study of a new treatment for hepatic cancer. by Kunieda, K. et al.
Br. J. Cancer (1993), 67, 668-673
Ltd., 1993
Implantation treatment method of slow release anticancer doxorubicin
containing hydroxyapatite (DOX-HAP) complex. A basic study of a new
treatment for hepatic cancer
K. Kunieda,l T. Seki,1 S. Nakatani,' M. Wakabayashi,' T. Shiro,' K. Inoue,' M. Sougawa,2
R. Kimura3 & K. Harada3
'Third Department ofInternal Medicine, Kansai Medical University, I-Fumizonocho, Moriguchi, Osaka 570; 2Department of
Radiotherapy, Cancer Institute Hospital, I-Ikebukuro, Toshimaku, Tokyo 170; 3PL Botanical Institute, PL Gakuen Women's Jr
College, I-Kamiyamacho, Tondabayashi, Osaka 584, Japan.
Summary We performed an experimental study on slow releasing anticancer drug implantation treatment as
a new therapy for hepatocellular carcinoma. Hydroxyapatite (HAP) was chosen for the carrier material and
doxorubicin hydrochloride (DOX) for anticancer agent. DOX-HAP was produced by adsorbing DOX to
porous HAP particles of 1375 ± 125 gm diameter using the freeze drying method. In vitro experiments showed
slow release of the drug resulting in the steady release of DOX from HAP for I month duration. In healthy
white rabbits with DOX-HAP implantation in the liver, serum DOX was not detectable, and DOX release rate
was stable at the implanted region after 7, 14, and 21 days. When DOX-HAP (DOX; 100mg kg-') was
administered to mice with sarcoma 180, an improved survival rate was observed without acute toxicity.
We also found that VX2 liver tumour growth on white rabbit was inhibited by implantation of DOX-HAP,
without acute toxicity. We hope that DOX-HAP implantation therapy will open up new avenues for the
treatment of hepatoma.
The introduction of interventional injection of Podophyllin
(Semple, 1948) and intraarterial injection of nitrogen mustard
(Bierman et al., 1950; Klopp et al., 1950), has facilitated the
development of targeting therapies for malignant solid
tumours, such as selective intraarterial or intratissue injection
of anticancer drugs, which aim at the prolongation of the
effect of anticancer drugs. Anticancer drugs, however, have a
very low therapeutic index because of their strong cytotox-
icity and the large dosage required to produce the desired
effect. To overcome these problems, targeting chemotherapy
with drug-carrier complexes was invented, using a microcap-
sule (Kato et al., 1980), fat (Takahashi et al., 1973), carbon
(Hagiwara et al., 1987), dextran (Hashida et al., 1981), and
lipiodol (Konno et al., 1983, 1984).
We selected hydroxyapatite (HAP) as a drug-carrier based
on its confirmed safety as an osteofilling. We produced a
slow-releasing anticancer drug complex, DOX-HAP by
physically adsorbing doxorubicin (DOX) to HAP by a freeze
drying method. The implantation of this complex was done
with the guidance of ultra-sound. The properties and
anticancer effect of this implantation therapy were inves-
tigated in the transplantable tumours, VX2 carcinoma and
sarcoma 180(S-180).
Materials and methods
Preparation ofDOX-HAP
HAP is an inorganic substance analogous to bone, with a
structural formula of Ca,0(PO4)6(OH)2 and a base material
with a Ca/P atomic ratio of 1.67. The substrate was prepared
by mixing Ca(OH)2 and H3PO4 employing a precipitation
method (Uchida et al., 1985). The precipitated material was
then dried and sintered at 1,200°C. The chemical composition
of resulting material was confirmed as pure HAP by X-ray
diffraction. These HAP particles (1,375 ± 125ILm) had a
specific surface area of 25 m2 g' and porosity of 80%, and
could pass through a 14 G biopsy needle (Asahi-Kogaku Inc.
Tokyo, Japan) (Figure la). Fifty mg of DOX (Kyowahakko
Co. Ltd. Tokyo, Japan) in 1 ml of phosphate buffered saline
(PBS, pH 3.0) were added to 500 HAP particles and stirred,
then left still in negative pressure. DOX-HAP complex was
then made by a freeze drying method (Figure lb). One
particle of DOX-HAP was shown to contain 0.1 ± 0.08 mg
of DOX. For the implantation, a biopsy needle was inserted
into the tissue under the guidance of ultrasound, an inner
needle was removed, DOX-HAP complex particles were
poured into the outer needle and buried by pressing the inner
needle manually (Figure lc).
Assay ofrelease ofDOX, in vitro study
One hundred particles of DOX-HAP in 1 ml of PBS were
gently shaken in a test tube at 37°C (n = 3), and the amount
of released DOX was measured every 24 h for 60 days. The
quantitative analysis of DOX was done with autospectro-
metry (UV-2100 Shimazu-Seisakusho, Tokyo, Japan), using
the maximum absorption of DOX spectrum of 480.0 nm.
Rabbit study
White rabbits (2.8-3.3 kg) were fixed in supine position and
placed under Ketamine hydrochloride (1 mgkg-') intramus-
cular (i.m.) anesthesia. The right lobe of the liver was
exposed with a median incision on the abdomen and
implanted with DOX-HAP (DOX, 1 mg, HAP group), then
closed. Animals were killed after 6h, 1, 3, 7, and 14 days.
Serum was collected from the femoral vein at 15, 30, 45 s; 1,
3, 15, 45, 60min; 3 and 6h; 1, 3, 7, and 14 days. Tissues
(1 g) without implanted DOX-HAP particles were also
obtained from the implanted area, intact liver lobe, heart
(apex), lung (upper lobe), and kidney (superior extremes).
Free DOX concentration was measured using a high perfor-
mance liquid chromatography (HPLC) method. The respec-
tive tissue was immersed into Kolthoff buffer, and was
homogenised. Then, the disrupt tissue was added to a 50:50
(v/v) solution of toluene/butanol, shaken, and the layer of
organic solvent was dried. The residue was disrupted in
solvent again by ultrasonication. The supernatant was used
as the injection sample of HPLC. The conditions of HPLC
were as follows: wave length 470.0 nm; column oven 40°C;
column Nucleosil 10 C18 (4 mm x 25 cm) from Gaskuro
Industry, Inc (measurable limit = 0.089 itg g-'). The group
which had only DOX injection (1 mg 0.5 ml-' saline) in the
right liver lobe by a 23 G needle after laparotomy was used
as the control.
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Figure 1 a, HAP particle (1,375 ± 125;Lm mean ± s.d.). b, DOX-HAP particle (DOX; 0.1 mg). c, DOX-HAP particles passing
through a 14 G biopsy needle.
Measurement ofanticancer effect in sarcoma 180 tumour
S-180 cells which had been maintained in the abdominal
cavity of the ddY mice (23-28 g) were collected aseptically
and made into a cell suspension of 1.0 x 108 cells ml-'.
0.1 ml of this suspension was injected with a 23 G syringe
subcutaneously into the thigh of the same strain of mouse.
The DOX-HAP (DOX, 20, 40, 60, 80 and 100 mgkg-', HAP
group, n = 20) was implanted by open surgery in the tumour
after the tumour volume reached to 500 ± 23 mm3 (tumour
volume V = 4nc/3 x length x width x height). The mice which
had been injected with DOX alone intratumourally (i.t.) (10,
15, 20, 40, 60, 80 and 100mgkg-', n=20) and intra-
peritoneally (i.p.) (5, 10, 15, 20, 30 and 40mgkg', n = 20)
and non-treated mice (n = 20) were prepared as control
groups. The tumour volumes were then measured until their
size reached to 1,500 mm3. The anticancer effect was
evaluated by LDM/7 and by tumour growth time (t.g.time).
LD50/7 was defined as the DOX dose which gave a 50%
survival rate within 7 days, and t.g.time as the days which
were required for a tumour to reach 1,500 mm3 from the first
treatment day. These two parameters were calculated by logit
analysis (Urano & Kahn, 1987). The survival rate of the
HAP group (DOX; 100 mgkg-') was evaluated by Kaplan-
Meier method (Kaplan & Meier, 1958).
The tumours were removed from the HAP group (DOX;
100 mg kg-') after 1, 3, 5, and 7 days of implantation. They
were then treated with formalin, paraffin embedding, and
hematoxylin-eosin stained, after which histologic analysis was
performed.
VX2 tumour
VX2 tumour in the femoral muscle of the white rabbit was
removed aseptically after 4 weeks of implantation. The
tumour was then finely cut in PBS and filtered with aseptic
gauze to prepare suspension of 8 x 107cells ml-'. The rabbit
was laparotomised by median incision under Ketamine
hydrochloride (1 mgkg-') i.m. anesthesia, 0.1 ml cell suspen-
sion was injected with a 26 G syringe into the liver paren-
chyma of the right lobe, and then closed. One week after the
implantation, the tumour volume (Vb) was measured. Rab-
bits with tumour sizes of 1 cm in diameter were selected for
further study. The DOX-HAP (DOX; 1 mgkg-') was
implanted inside the tumour by open surgery. The liver was
taken out after 7 and 14 days of implantation and tumour
volume (Va) was measured. Inhibition effect on tumour
growth was evaluated by Va(7)/Vb and Va(14)/Vb. The only
DOX (DOX; 1 mg kg', n =6) intratumour injection (i.t.)
group and a non-treated group (n = 6) were used as controls.
The concentration of free DOX in the HAP group on day
7 was measured in three different areas using the HPLC
method; (1) the tissues of DOX-HAP implanted tumour; (2)
the implanted tumour edge; (3) the intact liver tissue. The
intratumour group was the control.
After fixation of the tissue in 10% formalin, ultrasono-
graphic tomography was done and sections were made of the
same level. Sections were embedded in paraffin, hematoxylin-
eosin stained, and histologically examined for anticancer
effects of DOX-HAP.
Results
Assay ofrelease ofDOXin vitro study
The in vitro release pattern of DOX from DOX-HAP showed
that 33% of DOX was eluted by the 3rd day, but a stable,
slow 1% per day release was observed between the 5th and
28th days and 56% of the total DOX was eluted by the 28th
day (Figure 2).
Rabbit study
In the rabbit study, the DOX concentration in the blood was
always below a measurable level in the HAP group. How-
ever, it was 6.91 figg-' at 15 s after injection of only DOX.
After 45 min, it dropped back below a measurable level. In
the implanted tissue the HAP group had a peak of
41.0fg g-' of DOX concentration on the 3rd day, a decrease
to a plateau level of 10.3jig g-' on the 14th day and
10.8 ig g-' on the 21st day. The only DOX group, however,
showed a gradual and continuous decrease in DOX concen-
tration from 18.6igg-' at 6h to below a measurable level
on the 7th day. The DOX concentrations in the heart, lung,
kidney, and left lobe of the liver were under the measurable
limit in the HAP group after 1 day, but remained measurable
in the only DOX group until the 3rd day (Table I).670 K. KUNEIDA et al.
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Figure 2 In vitro release pattern of DOX from HAP into PBS (n = 3). The bar indicates mean ± s.e.
Anticancer effect on sarcoma-180 tumours
In the study ofLD50/7, a DOX concentration of 23.2 mg kg-'
for the i.t. group resulted in a 50% survival rate. A concen-
tration of 13.4 mg kg' yielded the same result for the i.p.
group. At a 40 mg kg-' DOX concentration, mortality was
100% in the i.p. group (Figure 3). Autopsies revealed no
obvious macroscopic metastasis. These findings were possibly
due to the toxic effect of DOX. However, the HAP group
showed no death, even with a DOX concentration of
100mg kg-'.
The inhibitory effect of the HAP on the tumour growth
was shown to be dependent on the DOX dose (Figure 4).
The times taken to reach a tumour volume of 1,500mm3
were 21.9 (20.2-23.8) days for the 100mgkg-' group, 18.1
(16.5-20.1) days for the 60mgkg-', and 14.6 (9.8-17.2)
days for the 20mgkg-' compared to 7.93 (7.80-8.11) days
for the control group. Administration of HAP alone
accelerated tumour growth probably due to its physical
stimulation. Figure 5 represents the tumour growth time (Y)
as a function of DOX dose (X). In the HAP group, a
linear-regression curve of y = 0.14 x + 9.29 (r = 0.98) was
obtained.
In the 50% survival of the ddY mice, there was a remark-
able difference between the HAP group (70.0 days) and the
non-treated group (41 days). In the i.p. group, 50% survival
was 49 days. In addition, 30% of the mice in the HAP group
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Figure 3 Survival within 7 days (LD50/7) after therapy for S-180
in ddY mice (n = 20). Implantation of DOX-HAP (HAP) (0),
injection of DOX alone into the tumour (i.t.) (0) and injection
of DOX alone to the peritoneal cavity (i.p.) (A).
Table I Tissue concentration of DOX after implantation and injection into liver
Liver Liver
Days (implanted site) (intact) Kidney Lung Heart
DOX-HAP (DOX: I mg) group
6h 15.8±2.79 0.09±0.1 0.12±0.1 0.14±0.25
1 10.5±2.65
3 41.0 2.33
7 6.29 1.31 -
14 10.3 1.68
21 10.8 ± 1.71
DOX injection group
6 h 18.6 ± 3.31 0.22 ± 0.21 1.34 ± 0.72 0.58 ± 0.24 0.37 ± 0.36
1 0.41 ±0.32 0.11 ±0.11 1.15 0.58 0.25 0.13 0.25 0.31
3 0.20 0.21 -
means ± s.d. for six samples, -: not detected, measurable level 0.089fg g- ' by the
HPLC method.
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Figure 4 Growth of S-180 in ddY mice after implantation of DOX-HAP. DOX 20 (A), 60 (A) and
particles) only (0). No treatment (A). Values are mean ± s.e. for 20 mice.
were still alive even after 120 days and these mice were cured.
On histological examination of S-180 1 day after implanta-
tion, hemorrhagic necrosis and phagocyte infiltration were
observed under integument and around HAP. Three days
later, the area of necrosis spread continuously with
phagocytes around HAP. Five days later, vacuolation of
tumour cells, hyperplasia of fibrous tissues, and oncolysis
expansion around vessels at a distant area from the HAP
were observed. Seven days later, oncolysis expanded and
phagocyte infiltration around the remaining tumour cells was
noted.
Anticancer effect on VX2 tumour
VX2 tumour volume ratios [Va(7)/Vb] of non-treated group,
the i.t. group, and the HAP group were 18.6 ± 6.5,
0
0)
0
I-
q
20 40
100 (0) mgkg-'. HAP (25
16.0 ± 3.5, and 7.38 ± 3.5, respectively. Ratios of Va(14)/Vb
were 24.8 ± 3.9, 20.2 + 3.2, and 6.91 ± 3.3, respectively.
DOX concentrations inside the tumour on day 7 were
4.87 ± 1.9 tg g-I for the HAP group and 0.55 ± 0.93Itgg-'
for the i.t. group. DOX concentrations at the edge of the
tumour were 0.36 ± 0.59Itgg-' for the HAP group and
0.14 ± 0.20pgg-' for the i.t. group. VX2 liver tumour at the
7th day after DOX-HAP implantation histologically revealed
tumour necrosis and fibrocyte hyperplasia around HAP
(Figure 6).
Discussion
Recent treatments for non-resectable malignant liver tumours
have focused on local treatment. These targeting chemo-
Y = 0.14x + 9.29 r = 0.98
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Figure 5 Effect of DOX-HAP implantation therapy on S-180 tumour in ddY mice. Implantation of DOX-HAP (0). Injection of
DOX only to the tumour (0). Injection of DOX only to the peritoneal cavity (A) (n = 20).672 K. KUNEIDA et al.
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Figure 6 Histological appearance of VX2 tumour 7 days after DOX HAP implantation (H E stain x 100
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therapies include intraarterial chemotherapy (Doppman et
al., 1968; Goldstein et al., 1976; Klopp et al., 1950),
embolisation therapy (Nakamura et al., 1983; Yamada et al.,
1983), and percutaneous ethanol injection into hepatocellular
carcinoma (Seki et al., 1989, 1991; Sugiura et al., 1983).
However, there is a demand for a treatment which has a less
liver -and general toxicity or systemic side effect, in addition
to the local anticancer effect. Targeting therapies, using a
microcapsule, fat, and lipiodol methods have recently im-
proved (Audisio et al., 1990; Gregoriadis, 1977; Kato, 1983;
Kato et al., 1980, 1984; Konno et al., 1983, 1984; Widder et
al., 1979). These methods were made possible by primary
targeting through the nutrient artery of the tumour and
complete secondary targeting by adding the embolisation
effect. For patients with arterial shunt or tumour embolism,
however, these methods are not effective and retention of
drugs in the tumours is unreliable in many cases. In this
study, since DOX-HAP implantation therapy had a greater
survival rate than i.t. group and i.p. group, it is clear that
DOX-HAP implantation therapy is an effective method for
the tumour treatment.
We have developed a new method of slow release of an
anticancer agent using a carrier material implanted into a
liver tumour under an ultrasonic guide. After considering
safety, convenience (Uchida et al., 1985, 1989), and pos-
sibility of repetition, we chose HAP for the carrier material.
Saito et al. (1987), has previously reported the anticancer
effect of HAP with DOX injected in the tumour ofhepatocel-
lular carcinoma patient. However, from her experiments, it
was not clear whether the effect was due to the direct treat-
ment or to the slow release of DOX. To address this issue we
produced 1,375 ± 125 ,Lm diameter particles by sintering
HAP powder which could pass through a biopsy needle. The
advantages of our method include the reduction of the
material moved into the vessels and easy confirmation of its
location by ultrasound. We have produced a slow release
anticancer agent, DOX-HAP, by physical adsorption of
DOX to the surface and inner space of HAP by using freeze
drying method. Recently, the manifestation of the DOX
effect has been considered to be strongly correlated with the
contact duration (Ozawa et al., 1988, 1989). For this reason
we chose DOX which is comparatively effective on the
hepatoma. Some discrepancies exist between the results of
our in vitro and in vivo experiments, which we believe can be
explained by considering the time required for DOX to elute
into the blood stream around the implantation area. Once
the DOX began to elute, it displayed a stable slow release
pattern compared with other slow releasing agents. Our study
on rabbits showed that the DOX concentrations in serum
and organs other than the implanted area were always below
a measurable level and the high dose experiment on mice
with a tumour did not demonstrate any acute toxicity.
The anticancer effect of DOX-HAP on S-180 depended on
the dosage, however, tumour growth inhibition was offset by
high mortality due to acute toxicity in high doses in i.t.
groups and i.p. groups. Pathological examination revealed an
increase of tumour-necrosis around the implantation area
and the appearance of necrotic tissue around vessels until 7
days after the procedure. This led us to believe that DOX-
HAP produced an anticancer effect not only around the
implantation area, but eluted free DOX in the blood stream
resulting in the expansion of the necrotic area.
We believe that DOX-HAP implantation therapy is an
effective treatment with an efficient drug delivery system. We
also discover that careful choice of implantation area and
joint use of other therapies, such as embolisation therapy and
percutaneous ethanol injection, are required to increase the
anti-tumour effect.
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